Torax Medical recently reported that the U.S. Food and Drug Administration (FDA) has approved a next generation LINX Reflux Management System that is MR conditional in magnetic resonance imaging (MRI) systems up to 1.5 Tesla (1.5T), which represents about 90 percent of MRI systems in use in the U.S.
According to a media release, the LINX 1.5T design contains a different grade of magnets that have a higher resistance to being demagnetized when subjected to external magnetic fields (i.e. MRI).
"We are pleased to make this next generation LINX device available to patients seeking relief from their reflux symptoms while broadening their access to diagnostic imaging options after treatment," said Todd Berg, President and CEO of Torax Medical.
Patients considering the LINX procedure should consult their healthcare provider regarding any questions related to MR imaging. Patients who have already received a LINX implant should consult their provider prior to undergoing any MRI tests.
Torax Medical is a privately held medical device company
((Comments on this story may be sent to firstname.lastname@example.org))
(c) 2015 ProQuest Information and Learning Company; All Rights Reserved., source Trade Publications